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The article discusses the effect of synbiotic therapy on the qualitative and quantitative changes in colonic microbiota 
in preschool children with community-acquired pneumonia. A total of 33 children aged from 1 to 3 years were included 
in the study. All patients were divided into two groups. The first group consisted of 17 children who received standard 
therapy. The second group consisted of 16 patients, whose treatment was supplemented with a synbiotic preparation at a dose 
of one sachet per day. The assessment of colonic microbiota was conducted in 33 patients with community-acquired 
pneumonia before treatment and on treatment days 12–14. The control group consisted of 20 healthy age and 
sex-matched  children. Bacteriological study of gut microflora was conducted using the Epshtein-Lytvak method. 
The evaluation of the microflora composition changes in children suffering from community-acquired pneumonia showed 
an intensification of gut microflora imbalance after standard therapy. When studying the effectiveness of the synbiotic 
preparation in patients with community-acquired pneumonia, it was found that the state of colon microbiocenosis in patients 
who received complex therapy with synbiotic drug significantly improved compared to children treated with standard regimen. 
Thus, of the use of synbiotic therapy in patients with community-acquired pneumonia improves or fully restores 
gut microflora in some cases. This preparation can serve as a safe and convenient way to restore gut microflora balance 
and prevent the development of gastrointestinal pathologies.
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W artykule omówiono wpływ terapii synbiotycznej na zmiany jakościowe i ilościowe w mikroflorze jelita grubego u dzieci 
w wieku przedszkolnym chorujących na pozaszpitalne zapalenie płuc. Badaniem objęto 33 dzieci w wieku od 1 do 3 lat. 
Pacjentów podzielono na dwie grupy. Pierwsza liczyła 17 dzieci otrzymujących standardowe leczenie. Do drugiej grupy 
włączono 16 pacjentów, u których leczenie uzupełniono podawaniem preparatu synbiotycznego w dawce jedna saszetka 
na dobę. Ocenę mikroflory jelita grubego u 33 pacjentów przeprowadzono przed rozpoczęciem leczenia oraz 
w dniach 12.–14. terapii. Do grupy kontrolnej włączono 20 zdrowych dzieci dobranych pod względem wieku i płci. 
Badanie bakteriologiczne mikroflory jelitowej przeprowadzono metodą Epshtein-Lytvak. Ocena zmian w składzie mikroflory 
u dzieci z pozaszpitalnym zapaleniem płuc wykazała nasilenie zaburzeń równowagi mikroflory jelitowej u dzieci 
otrzymujących standardowe leczenie. W odniesieniu do skuteczności preparatu synbiotycznego u pacjentów z pozaszpitalnym 
zapaleniem płuc wykazano istotną poprawę mikrobiocenozy jelitowej u dzieci otrzymujących kompleksowe leczenie 
uzupełnione terapią synbiotyczną w porównaniu z dziećmi leczonymi według standardowego schematu. Zatem zastosowanie 
terapii synbiotycznej u dzieci z pozaszpitalnym zapaleniem płuc poprawia lub w pełni przywraca prawidłową mikroflorę 
jelitową w pewnych przypadkach. Preparat ten można stosować jako bezpieczny i dogodny sposób przywracania równowagi 
mikroflory jelitowej oraz zapobiegania patologiom przewodu pokarmowego.
Słowa kluczowe: pozaszpitalne zapalenie płuc, dzieci w wieku przedszkolnym, mikroflora jelitowa
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INTRODUCTION
Community-acquired pneumonias (CAP) take top spot in the structure of general morbidi-ty among children and remain one of the 10 key 
causes of mortality in economically developed countries. 
According to the World Health Organization statis-
tics, 155 million cases of infant pneumonia are record-
ed annually. Cases of death due to pneumonia are ob-
served mainly in infants (11,3 per 100,000 live births), 
but also in adolescents and children with immune de-
fence disorders(1). Despite advances in modern medicine, 
pneumonia still remains one of the most serious diseases. 
It is associated not only with high mortality risk and dif-
ferent complications, but also with a long recovery period 
with asthenic syndrome manifestations and vegetative reg-
ulation disorders. The degree of predisposition to different 
inflammatory reactions of the respiratory system and the 
peculiarities of their clinical course are connected with the 
state of immunological reactivity(2). Typical large bowel mi-
croflora is known to play an important role in the mainte-
nance of the immunological homeostasis. Eubiotic auto-mi-
croflora representatives can oppress the growth of various 
pathogenic and nonpathogenic microorganisms, intensi-
fy the phagocytic activity of macrophages, monocytes and 
granulocytes as well as increase cytokine, IgA and cytoim-
munologic protection system synthesis(3–5). The spectrum 
of diseases whose pathogenic mechanisms are related to 
qualitative and quantitative disorders of the gut microbio-
ta is growing at present. The diseases of bronchopulmona-
ry organs belong to this spectrum. The associated dysbiotic 
gut changes, having reached a certain level, worsen the clin-
ical course of the underlying disease. As a result, the sever-
ity of clinical symptoms increases, and so does the disease 
duration, while the general condition, treatment parameters 
and patients’ quality of life deteriorate. Once pneumonia 
is diagnosed, antibacterial therapy is prescribed immedi-
ately as a rule. At the same time, antibacterial therapy plays 
a key role in the gut biocenosis disorders. Antimicrobials 
are known to lead to microecological disorders even when 
used parenterally(2).
Unfortunately, modern medicine does not always take into 
account the need to maintain the symbiosis of the child’s 
body with its microflora. Biotherapy, which includes 
mainly probiotic and prebiotic preparations, is considered 
the most optimal method for the prophylaxis and correc-
tion of microbiocenosis imbalance. According to some au-
thors, probiotic and antibiotic co-administration prevents 
dysbiotic and immunological disorders, potentiates the ef-
fect of antibiotic therapy and reduces the duration of dis-
ease exacerbation(6).
Therapeutic and preventive effects of probiotics are asso-
ciated with:
• activation of local macrophages to increase antigen pre-
sentation of B lymphocytes and increased local and sys-
temic production of secretory immunoglobulin A (IgA);
• modulation of cytokine profiles;
• bacteriocin secretion to inhibit pathogens;
• participation in the regulation of biofilms functioning on 
the mucous membranes;
• food digestion and competition with pathogens for 
nutrients;
• local pH change to create unfavourable local environ-
ment for the development of pathogens;
• neutralisation of superoxide radicals;
• stimulation of epithelial mucin production;
• enhancing the gut barrier function;
• competitive interaction for the receptors on the colon 
mucous membrane(7–9).
Given the fact that populations of normal microflora repre-
sentatives are able to grow rapidly in the presence of nour-
ishing substrates, the use of synbiotic is appropriate as pre-
biotics perform a preparatory function for the development 
of probiotic culture. Symbiotic effect is based on the syn-
ergism between probiotics and prebiotics. As a result, not 
only microorganisms – probiotics are most effectively im-
planted in the gastrointestinal tract of the host, but also 
one’s own microflora is stimulated. As a result, human met-
abolic processes normalise(10).
The aim of our research was to assess the effects of a syn-
biotic preparation on gut microflora in preschool children 
suffering from CAP.
The preparation contains the Bifidobacterium (BB-12) 
strain, which maintains and regulates gut microflo-
ra balance. It has a wide range of antagonistic activities 
against pathogenic and opportunistic bacteria (OB) as 
well as strong colonisation ability. Bifidobacterium BB-12 
shows acid and gall tolerance, has predicted antibiotic re-
sistance level, enhances the body’s immunity and restores 
the natural protection of the child’s organism. It is impor-
tant that these bacteria have been awarded GRAS (gener-
ally recognised as safe) status, characterising them as def-
initely safe in use. The preparation is available in a sachet 
form, which contains more than 4 billion of lyophilised cells 
of Bifidobacterium BB-12 and a prebiotic component – frui-
toligosaccharide. Acidolac Baby can be used in children 
aged from 1 to 3 years (1 sachet per day) and over 3 years 
(1 sachet 1–2 times a day). The presence of prebiotics (frui-
toligosaccharide) in the formulation selectively stimulates 
and regulates the growth of probiotic components, allowing 
for more rapid and longer-lasting effects compared to prep-
arations consisting of probiotics or prebiotics alone.
MATERIAL AND METHODS
The study included 33 children aged from 1 to 3 years, who 
underwent a course of CAP treatment in the infectious 
unit No. 1 of the Sumy Children’s Clinical Hospital named 
after St. Zinaida. All patients were divided into two groups. 
The first group consisted of 17 children who received stan-
dard therapy according to the Ukrainian Ministry of Health 
Protocol No. 18 of health care for children with pneumonia 
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dated January 13th, 2015. The second group consisted 
of 16 patients with CAP, whose treatment course was sup-
plemented with a synbiotic preparation at a dose of one sa-
chet per day.
The characteristics of colon microbiota was conducted 
in 33 patients with CAP before treatment on day 1 of ad-
mission to hospital (groups I and II), in 17 patients on days 
12–14 of standard treatment (group I) and in 16 patients on 
days 12–14 of the therapy supplemented with the synbiotic 
preparation (group II).
The control group consisted of 20 age and sex-matched 
healthy children.
Pneumonia diagnosis was verified based on complaints 
from the parents of affected children, medical history, ob-
jective symptoms as well as data obtained using laborato-
ry and instrumental methods according to the children’s 
care protocols of the “Children’s pulmonology” approved 
by the Ukrainian Ministry of Health Order No. 18 dated 
January 13th, 2005.
The study of microflora structural peculiarities was per-
formed using R.V. Epshtein-Lytvak method (1977). 
It is based on the calculation of bacteria quantity found 
in the dilution of 1 g of faeces seeded in selective nutri-
ent media(11).
The indicator of microbial colonisation intensity (microbe 
count) was determined by counting the colonies with the 
help of colony forming units (CFU). Colonisation intensi-
ty was expressed as a decimal logarithm (1–12 lg CFU/g) 
in order to facilitate the calculation.
Statistical processing of final results was carried out us-
ing the standard statistical Microsoft Excel, adapted 
for biomedical research with Student criterion (t) used 
for the estimation of validity difference in absolute aver-
age values. If t = 1.96, p < 0.05, there is a significant differ-
ence between indicators.
The investigation was approved by the Institutional 
Bioethics Committee and conforms the principles out-
lined in the Declaration of Helsinki with subsequent 
amendments.
DISCUSSION OF RESULTS
The analysis of gut microflora in children with CAP showed 
considerable changes in qualitative and/or quantitative 
composition of aerobic and anaerobic bacteria in the first 
days of hospitalisation.
Evaluation of colonic dysbiotic changes in CAP patients 
at the beginning of the disease showed a reliable decrease 
of bifidobacteria [(5.97 ± 0.41) lg CFU/g (р < 0.001)] and 
lactobacteria quantity [(6.35 ± 0.44) lg CFU/g (р < 0.001)] 
compared to children from the control group (Tab. 1).
Evaluation of changes in the microflora composition in chil-
dren suffering from CAP showed intensified gut microflora 
imbalance after standard therapy. The number of bifidobac-
teria [(4.27 ± 0.52) lg CFU/g (р < 0.05)] and lactobacte-
ria [(4.63 ± 0.54)  lg CFU/g (р < 0.05)], Escherichia coli 
[(5.25  ±  0.34)  lg  CFU/g (р  <  0.05)] decreased, while 
the number of OB [(3.70 ± 0.41) lg CFU/g (р < 0.05)] 
Bacteria Control group,  
lg CFU/gr (n = 20)
Groups I and II at baseline,  
lg CFU/gr (n = 33)
Group І after treatment, 
lg CFU/gr (n = 17)
Group ІІ after treatment,  
lg CFU/gr (n = 16)
Bifidobacteria 8.59 ± 0.33 5.97 ± 0.41
p1–2 < 0.001
4.27 ± 0.52
p1–3 < 0.001
p2–3 < 0.05
6.59 ± 0.89
p1–4 > 0.05
p2–4 > 0.05
p3–4 < 0.05
Lactobacteria 8.46 ± 0.25 6.35 ± 0.44
p1–2 < 0.001
4.63 ± 0.54
p1–3 < 0.001
p2–3 < 0.05
6.57 ± 0.65
p1–4 < 0.05
p2–4 > 0.05
p3–4 < 0.05
Total number of Escherichia coli 6.83 ± 0.19 6.21 ± 0.26
p1–2 > 0.05
5.25 ± 0.34
p1–3 < 0.001
p2–3 < 0.05
6.40 ± 0.39
p1–4 > 0.05
p2–4 > 0.05
p3–4 < 0.05
OB 1.88 ± 0.27 2.67 ± 0.27
p1–2 > 0.05
3.70 ± 0.41
p1–3 < 0.01
p2–3 < 0.05
2.14 ± 0.19
p1–4 > 0.05
p2–4 > 0.05
p3–4 < 0.01
Staphylococci 0.26 ± 0.14 0.90 ± 0.27
p1–2 > 0.05
1.67 ± 0.44
p1–3 < 0.01
p2–3 > 0.05
0.73 ± 0.25
p1–4 > 0.05
p2–4 > 0.05
p3–4 > 0.05
Fungi Candida 0.91 ± 0.27 1.85 ± 0.37
p1–2 > 0.05
3.16 ± 0.54
p1–3 < 0.01
p2–3 > 0.05
1.81 ± 0.27
p1–4 > 0.05
p2–4 > 0.05
p3–4 > 0.05
p1–2 – differentials between children at baseline and control group; p1–3, p1–4 – differentials between control group and groups I and II; p2–3, p2–4 – differentials between 
groups I and II at baseline and after treatment; p3–4 – differentials between groups I and II after treatment.
Tab. 1.  Dynamics of gut microflora changes in preschool children suffering from CAP depending on therapy (M ± m; M – arithmetic mean, 
m – mean error of arithmetic mean)
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increased in children from group I compared to relevant in-
dicators in the acute phase of disease. A significant decrease 
of bifidobacteria (р < 0.001), lactobacteria (р < 0.001), 
and Escherichia coli (р < 0.001) titres as well as increased 
OB, staphylococci and Candida titres (р < 0.01) were found 
compared to controls.
The obtained research data indicate that the use of standard 
therapy in children with CAP resulted in the absence of pos-
itive changes of the abovementioned indicators. Indigene 
microflora has a great stimulatory impact on local gut im-
munity; therefore, a decrease in lactobacteria and bifido-
bacteria reduced antagonistic and immunogenic properties 
of normal gut microflora. This, in turn, increased the num-
ber of pathogenic and opportunistic microorganisms as well 
as the imbalance in the ratio of obligate and facultative mi-
croorganisms in the normal gut microflora. This is in line 
with other authors(8,9). Thus, the decrease in the composition 
of some microbiota representatives can cause an imbalance 
of the admirable system of local protection and even pro-
mote the development of pathological conditions.
When assessing the effectiveness of the synbiotic prepara-
tion in patients with CAP it was found that colonic micro-
biocenosis significantly improved in patients who received 
this preparation compared to children treated with stan-
dard regimen (Tab. 1).
The analysis of the composition of gut microbiota in chil-
dren from group II revealed a significant increase of bifi-
dobacteria [(6.59 ± 0.89) lg CFU/g (р < 0.05)], lactobacte-
ria [(6.57 ± 0.65) lg CFU/g (р < 0.05)], and Escherichia coli 
[(6.40 ± 0.39) lg CFU/g (р < 0.05)] as well as a decrease 
of opportunistic microflora titres [(2.14 ± 0.19) lg CFU/g 
(р < 0.01)] compared to group I (Tab. 1). The composition 
of bifidobacteria, Escherichia coli, OB, staphylococci and 
fungi Candida normalised in children in group II.
Thus, the obtained research data prove the effectiveness 
of synbiotic preparation in patients suffering from CAP. 
The preparation improves or fully renews the state of gut 
microflora in some cases.
CONCLUSIONS
All preschool children included in the study showed a dis-
balance of gut microflora composition with decreased bi-
fidobacteria and lactobacteria in the acute phase of CAP.
After standard therapy without the symbiotic preparation, 
a further significant decrease of bifidobacteria, lactobacte-
ria, and Escherichia coli titres and an increase in the number 
of opportunistic bacteria were found in children with CAP.
Inclusion of synbiotic preparation in the therapy of patients 
with community acquired pneumonia promoted normal-
isation of bifidobacteria, Escherichia coli, Staphylococcus, 
Candida and opportunistic microflora.
This preparation can serve as a safe and convenient way to 
restore gut microflora balance and prevent the development 
of gastrointestinal tract pathological conditions.
Further research of the relationship between microbiota 
changes and immune system indicators is needed in chil-
dren with CAP, who receive a synbiotic preparation to pre-
vent complications of antibiotic therapy.
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